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ABSTRACT 
Vertebrate glycoproteins and glycolipids are synthesized in complex biosynthetic pathways localized 
predominantly within membrane compartments of the secretory pathway. The enzymes that catalyze these 
reactions are exquisitely specific, yet few have been extensively characterized due to challenges 
associated with their recombinant expression as functional products. We used a modular approach to 
create an expression vector library encoding all known human glycosyltransferases, glycoside hydrolases, 
sulfotransferases, and other glycan modifying enzymes. We then expressed the enzymes as secreted 
catalytic domain fusion proteins in mammalian and insect cell hosts, purified and characterized a subset 
of the enzymes, and determined the structure of one, the sialyltransferase ST6GALNAC2. Many enzymes 
were produced at high yields and similar levels in both hosts, but individual protein expression levels 
varied widely. This expression vector library will be a transformative resource for recombinant enzyme 
production, broadly enabling structure-function studies and expanding applications of these enzymes in 
glycochemistry and glycobiology. 
  
 3 
Cell surface and secreted glycoproteins and glycolipids contribute to numerous interactions with the 
extracellular environment that influence cellular physiology and pathology1,2. These interactions are 
strikingly diverse and include molecular recognition events that drive cell surface signaling, cell adhesion, 
and modulation of receptor half-lives and dynamics, among others2. Terminal glycan structures also direct 
cellular targeting and clearance of circulating glycoproteins, including most recombinant human 
therapeutics, and define many pathogen and toxin tropisms2.  
Numerous challenges remain in the study of glycan structures and their contributions to 
physiological processes. A recent study3 concluded that new and transformative methods are required to 
fill the technology gaps necessary for carbohydrate-based applications in health, energy, and materials 
sciences. The roadmap goals advanced for technology development included the enzymes involved in 
glycan synthesis, modification, and catabolism. These enzymatic reagents were emphasized not only 
because they would advance our understanding of fundamental glycan biosynthetic and catabolic 
processes3, but also for their utility in novel chemoenzymatic glycan synthesis, which has numerous 
applications in biological and biomedical studies,  as standards for glycomic analysis, for installation and 
manipulation of glycan structures in complex biological systems, and use in development of glycan-
related therapeutic applications, among others.  
Glycan biosynthesis occurs predominantly within the secretory pathway1, where glycosyltransferases 
(GTsa) use sugar donor precursors to extend oligosaccharide chains and glycoside hydrolases (GHs) 
cleave glycan structures during oligosaccharide maturation. Several factors contribute to the diverse 
glycan products of these complex enzymatic reactions. Most notably, glycan elaboration is controlled by 
the availability, abundance, and specificities of the enzymes (“glycoenzymes”) involved in glycan 
synthesis and catabolism4. Unlike RNA transcription and protein translation, these complex metabolic 
pathways are not template-driven. Thus, the keys to understanding glycan diversity and function lies in 
deciphering glycoenzyme specificities, structure-function relationships, and processes regulating their 
activities.  
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In mammals, ~700 enzymes and proteins contribute to glycan extension, modification, recognition, 
and catabolism4 in generating the full collection of ≥7,000 vertebrate oligosaccharide structures5. These 
enzymes include ~200 GTs and ~80 GHs (Supplementary Tables 1 and 2), which have been classified 
into 44 and 28 discrete sequence families, respectively, in the Carbohydrate Active Enzymes (CAZy) 
database6. Members of a given GT family generally have a similar protein fold, but frequently have 
distinct acceptor substrate profiles and can have different sugar donor specificities7,8.  Thus, subtle 
differences in protein structures between enzymes with otherwise similar protein folds produce 
glycoenzymes with unique catalytic specificities. These differences in substrate recognition among the 
GTs expressed in a given cell are critical factors determining the diversity of glycan structures in animal 
systems4. 
Many challenges remain in advancing our understanding of vertebrate glycosylation machinery at a 
molecular level. In general, only ~1% of the enzymes in a given GT or GH family have been 
characterized6 and structural studies have been performed on only a minor subset of these enzymes. For 
mammalian glycoenzymes, this reflects challenges associated with their recombinant expression, as 
evidenced by the deposition of only 28 of 202 vertebrate GT structures in the PDB6,8. A few mammalian 
GTs have been expressed in bacteria as either soluble truncated catalytic domains9 or with in vitro 
refolding10, but these examples are extremely rare8. More commonly, mammalian GT expression in 
bacteria yields non-functional protein aggregates because these enzymes require glycosylation, disulfide 
bonding, and chaperones that occur uniquely within the eukaryotic secretory pathway11. Large-scale 
efforts to produce glycoenzymes in cell free systems have not been reported. Thus, the most successful 
approach has been to produce recombinant glycoenzymes in eukaryotic hosts, but this has been restricted 
to small-scale expression studies for relatively focused biochemical goals8. Broad access to large 
quantities of the mammalian glycoenzymes would be greatly enhanced by the development of a unified, 
high-throughput expression platform that could be applied to all glycoenzymes in a modular format. 
We describe here an expression vector library encoding all known human glycoenzymes for 
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production in either mammalian (HEK293) cells12 or baculovirus-infected insect cells13. This is the first 
universal platform for the production of all human GTs, GHs, sulfotransferases (STs), and various other 
glycan modifying enzymes and employs the transfer of glycosylation enzyme coding cassettes into 
custom-designed plasmid or baculovirus expression vectors for recombinant glycoenzyme production in 
mammalian cells, insect cells, E. coli, or other hosts. We demonstrate the successful expression and 
secretion of a large set of mammalian glycoenzymes in mammalian cells and the baculovirus-insect cell 
system (65% secreted at ≥10 mg/L), generating quantities of the recombinant products sufficient for 
enzymatic and structural characterization, as well as glycan synthetic applications. We also demonstrate 
the purification of a subset of the GTs as a proof of concept and a complete enzymatic characterization 
and structural determination with the sialyltransferase, ST6GALNAC2, in complex with the donor analog 
CMP. Thus, we demonstrate that the expression vector library and resulting recombinant products provide 
a significant resource enabling detailed studies on these enzymes, as well as a source of novel enzymatic 
tools for a wide array of biochemical and biomedical applications. 
RESULTS  
Design of enzyme coding regions: A comprehensive list of >700 human glycoenzymes and proteins 
collected during prior glycogene transcript profiling efforts4 was used to extract a subset of 339 genes 
comprising all human GTs, GHs, STs, and numerous other glycan modifying enzymes (Supplementary 
Tables 1 and 2). Based on annotations in UniProt14, this list includes 187 protein coding regions with an 
NH2-terminal transmembrane domain (TMD; 56.2%) and 22 with a COOH-terminal TMD (6.6%). In 
addition, 28 were multipass or internal TMD enzymes (8.4%), 72 contained NH2-terminal signal 
sequences (21.6%), and 24 were predicted to be cytosolic (no TMD or signal peptide, 7.2%).  
We used a modular expression vector design to enable transfer of truncated enzyme coding regions 
into custom, host-specific expression vectors by Gateway recombination15. Glycoenzyme coding regions 
were truncated at their NH2- or COOH-termini and fused in-frame at their respective truncation sites with 
a sequence encoding a tobacco etch virus (TEV) protease recognition and cleavage site16. These coding 
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region cassette sequences were then placed into a plasmid vector containing flanking Gateway 
recombination sites (Gateway “donor” clones, Fig. 1 and Supplementary Fig. 1). Custom expression 
vectors were then prepared harboring host-specific promoter elements, fusion protein sequences and 
complementary Gateway recombination sites (Gateway destination “DEST” vectors; Fig. 1 and 
Supplementary Figs. 1 and 2). Recombination of the donor cassette coding regions with host-specific 
DEST expression vectors yielded the final collection of expression vectors containing host-specific 
transcription and translation elements that drive fusion protein expression with vector-encoded tags.  
For most coding regions, a single construct was designed as either an NH2- or COOH-terminal fusion 
(Fig. 1 and Supplementary Fig. 1). For example, the most common native topology for the mammalian 
glycoenzyme collection was an NH2-terminal TMD that initiates co-translational membrane insertion and 
provides membrane tethering and localization within the secretory pathway. The COOH-terminal ends of 
the coding regions contain the corresponding catalytic domains, which are topologically inside the lumen 
of the secretory pathway compartment. The TMD anchors are often dispensable for catalysis and can be 
deleted by truncation and replaced with other protein sequences, such as fusion tags, at the NH2-terminal 
end of the coding region as long as the proteins are expressed within the context of the eukaryotic 
secretory pathway11. Entry into the secretory pathway is mediated by an exogenous NH2-terminal signal 
sequence, which is part of the fusion tag assembly, and following entry, the catalytic domains are 
eventually secreted into the culture medium17. Thus, replacement of the NH2-terminal TMD with a TEV 
protease cleavage site16 and transfer of these coding regions into Gateway donor plasmids harboring 
flanking attB recombination sites produces a library of glycoenzyme truncations (Fig. 1 and 
Supplementary Fig. 1) that can be transferred to host-specific expression vectors harboring additional 
upstream fusion sequences, including an NH2-terminal signal sequence (Supplementary Figs. 2 and 3). 
Constructs encoding multipass transmembrane or cytosolic enzymes or enzymes with NH2-terminal 
signal sequences were designed to include their respective full length or truncated coding regions, with a 
COOH-terminal TEV protease cleavage site appended in place of the termination codon during transfer to 
 7 
a Gateway donor plasmid (Fig. 1, Supplementary Fig. 1 and Supplementary Tables 1-3). The fusion 
sequences were then extended downstream of the TEV site upon transfer to the final expression vectors 
via Gateway recombination (Supplementary Figs. 1 and 2). Thus, all coding regions were initially 
generated as a library of Gateway donor clones encoding either NH2-terminal or COOH-terminal TEV 
site fusions (Fig. 1 and Supplementary Fig. 1) and subsequently transferred to custom Gateway DEST 
vectors specific for expression in each host system (Supplementary Figs. 2 and 3).  
Strategies for capturing coding regions as Gateway donor clones involved PCR with Mammalian 
Gene Collection18 clones or human tissue cDNAs as templates, followed by Gateway BP recombination15 
into donor vectors (Fig. 1 and Supplementary Fig. 1). A total of 255 of the glycoenzyme coding regions 
(66%) were captured using this strategy (Table 1), while the remaining 132 glycoenzyme coding regions 
were synthesized with human codon optimization (Fig. 1, Supplementary Fig. 1 and Supplementary 
Tables 1-3).  
Fusion protein strategies for mammalian cell expression: Custom Gateway-adapted DEST vectors 
for mammalian cell expression included a cytomegalovirus (CMV) promoter and alternative fusion 
protein strategies.  Each vector had a Gateway selection cassette comprising ccdB and CmR genes flanked 
by attR sites15 that was replaced upon insertion of target gene coding regions from Gateway donor clones 
(Fig. 2 and Supplementary Figs. 1-3). Three different custom mammalian NH2-terminal fusion vectors 
were developed using alternative tagging strategies (Supplementary Fig. 2). All three vectors contained 
an NH2-terminal signal sequence followed by an 8xHis tag and other fusion sequences. The pGEn1 vector 
was designed to add a StrepII tag19 after the His tag and before the Gateway recombination site. 
Alternatively, the pGEn2 vector added an AviTag20 after the His tag followed by a “superfolder” GFP 
domain21. Finally, pGEn3 was designed to add the AviTag, GFP domain, and an additional Ig Fc domain22 
after the His tag to facilitate homo-dimerization of the fusion protein. We also generated a parallel set of 
custom COOH-terminal fusion vectors (Supplementary Fig. 2). pGEc1 was designed to append a 
COOH-terminal 8xHis and StrepII tag, by analogy to pGEn1, whereas pGEc2 was designed to append 
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COOH-terminal GFP, AviTag, and 8xHis tags, by analogy to pGEn2 ((Supplementary Fig. 2). These 
designs enabled transfer of each of the glycoenzyme coding regions into multiple NH2- or COOH-
terminal fusion protein contexts (Supplementary Fig. 2). 
Target protein expression, secretion, and quantitation in mammalian cells: To test glycoenzyme 
production and secretion efficiencies provided by the fusion vector series, a collection of pGEn1, pGEn2 
and pGEn3 vectors encoding fourteen different GT29 sialyltransferase coding regions17 were used for 
transient expression in HEK293 cells (Fig. 2). Most fusion proteins were secreted at significantly higher 
levels with pGEn2 and pGEn3, as compared to pGEn1, suggesting the GFP fusion domain enhanced 
protein folding and secretion. While we observed minor differences in overall protein production, 
secreted protein levels were essentially identical with pGEn2 and pGEn3, based on GFP fluorescence 
(Fig. 2). Thus, pGEn2 and pGEc2 were chosen for further screening and characterization of the full 
collection of recombinant products as GFP fusions.  
The GFP fusion domain in the pGEn2 and pGEc2 vectors also provided an effective tag for protein 
quantitation during expression and purification (Figs. 2 and 3, and Supplementary Table 2). The overall 
expression level (cells + media) was ≥10 mg/L for 94% of the recombinant products (Fig. 3). In contrast, 
only 53% of the proteins were secreted at a level ≥10 mg/L. However, many of the cytosolic and 
transmembrane proteins were not designed for secretion. When we considered only proteins designed for 
secretion, 65% were secreted at a level ≥10 mg/L. An interesting observation from these studies was that 
there was no apparent correlation between the expression level and secretion efficiency (Fig. 3, upper 
panel), as some well-expressed proteins were poorly secreted and many poorly expressed proteins were 
efficiently secreted.  
To illustrate the variability of enzyme expression and secretion, we further examined twenty GT29 
sialyltransferases designed using a similar fusion protein strategy. These pGEn2 constructs were 
expressed and cell and media samples were subjected to fluorescence measurements (Fig. 3) and SDS-
PAGE (Supplementary Fig. 4). The data indicated a subset of the enzymes (ST6GAL1, ST3GAL1, 
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ST3GAL3, and ST3GAL4) were exceptionally well expressed and secreted. A second category (e.g. 
ST3GAL5) were well expressed, but poorly secreted. A third category of enzymes (e.g. ST3GAL6 and 
ST6GALNAC3) had overall poor expression. Finally, a fourth category (e.g. ST6GAL2 and 
ST6GALNAC1) were well expressed and secreted, but subject to proteolysis between the catalytic 
domain and GFP fusion during expression (Supplementary Fig. 4). Thus, the behavior of the expression 
products varied significantly even within a single family of structurally similar enzymes. Variations in 
protein expression and secretion were also seen within other protein families, as highlighted by the 
enzymes from GH27, GT29, and GT31 in Figure 3b, but also observed in many other GT, GH, and ST 
families (Supplementary Table 2).  
Fusion protein strategies for baculovirus expression: We also generated baculovirus expression 
vectors (BEVs) encoding most of the glycoenzymes as either NH2- or COOH-terminal fusions using a 
strategy analogous to that used for the mammalian expression plasmids (Supplementary Fig. 3). 
Custom-designed baculoviral DEST vectors were designed containing the polyhedrin promoter, fusion 
protein sequences, and a Gateway recombination and selection cassette comprised of herpes simplex virus 
1 thymidine kinase and E. coli b-galactosidase genes flanked by attR sites (Supplementary Fig. 3). 
BEVs contained either short NH2-terminal fusions comprised of a signal sequence, 8xHis tag, and StrepII 
tag, analogous to pGEn1, or longer NH2-terminal fusions comprised of a signal sequence, 8xHis tag, 
AviTag, and GFP domain, analogous to pGEn2. The COOH-terminal fusion BEVs (Supplementary Fig. 
3) encoded StrepII and 8xHis tags, analogous to pGEc1. The same glycoenzyme donor clones used for 
the mammalian expression constructs were used with the custom baculovirus DEST vectors to generate 
the final BEVs, which encoded glycoenzymes with either NH2-terminal or COOH-terminal fusions. Since 
generation of most of the BEV stocks was underway well before we determined the GFP fusion cassette 
was the preferable strategy for the mammalian expression vectors, screening efforts with BEVs focused 
on the shorter His/StrepII fusions, analogous to pGEn1. Protein expression and secretion in BEV-infected 
insect cells was profiled by immunoblotting with anti-His tag antibodies and scored using semi-
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quantitative values, as indicated in Figure 4 and Supplementary Table 2.  
Comparison of insect and mammalian cell expression: Comparison of protein expression and 
secretion in BEV-infected insect and transiently transfected mammalian cells revealed a similar overall 
trend (Fig. 4), in which fusion proteins that were well expressed and secreted in transiently transfected 
mammalian cells were also generally well expressed and secreted in BEV-infected insect cells. However, 
there was considerable scatter in the data, indicating one of the two expression hosts can in some cases 
more effectively express specific protein coding regions. 
Since different fusion protein strategies had been used to produce expression vectors for human and 
insect hosts, we generated BEVs encoding twenty GT29 sialyltransferases with NH2-terminal large tag 
fusions for direct comparison with equivalent mammalian GT29 expression constructs (Supplementary 
Fig. 4). Secreted fusion protein levels from BEV-infected insect cell cultures were significantly lower 
compared to equivalent fusion proteins from transiently transfected HEK293 cells. However, when 
specific protein productivities (GFP fluorescence units/cell/day) were calculated, sialyltransferase fusion 
protein expression levels in BEV-infected insect cells were only ~3-10-fold lower than in transiently 
transfected HEK293 cells (Fig. 5).  
Immunoblotting and fluorescence data indicated the sialyltransferase GFP fusion secretion 
efficiencies were quite variable in both hosts, with some proteins efficiently secreted while others were 
largely retained in the cells. Secreted protein levels were highly correlated for half of the fusion proteins 
in the two recombinant hosts (R2=0.99; Fig. 4). However, eight of the sialyltransferase fusion proteins 
were more highly secreted in mammalian cells and two were more highly secreted in the BEVs (Fig. 4b). 
Thus, the trend was similar to the expression data for the larger collection of the glycoenzymes (Fig. 4a), 
as a subset of proteins was more effectively secreted in either human or insect cells, but most were 
secreted similarly in the two different expression hosts. 
Purification of human glycoenzymes from mammalian and insect cell cultures: The 8xHis tags 
associated with the secreted enzyme fusion proteins allow direct affinity purification of the recombinant 
 11 
products from the conditioned media by immobilized metal affinity chromatography (IMAC). To 
demonstrate enzyme purification from both expression host systems, we used IMAC to isolate the GH29 
sialyltransferase GFP fusion proteins from mammalian or insect cell-free media.  The results showed we 
could obtain >50% yields for the more highly expressed enzymes, and could readily purify even some of 
the more poorly expressed proteins by scaling up the culture volumes (Fig. 5). In the mammalian 
expression host, a majority of the GT29 sialyltransferases could be purified at >10 mg/L of transfected 
cell culture, indicating a majority of the enzymes could be produced and purified at levels required for 
biochemical and structural studies. 
Structure determination ST6GALNAC2: To demonstrate the utility of the expression vector library 
for glycoenzyme characterization, we scaled up production of one of the sialyltransferase GFP fusions 
(ST6GALNAC2-pGEn2) in HEK293S (GnTI-) cells23 using a selenomethionine labeling protocol 
established in prior structural studies on rat ST6GAL117. IMAC purification of the secreted fusion protein 
was followed by concurrent in vitro cleavage with TEV protease and endoglycosidase F1 (EndoF1). 
Further IMAC purification and gel filtration yielded the ST6GALNAC2 catalytic domain devoid of all 
tag sequences with N-glycans trimmed to a single GlcNAc residue (Supplementary Fig. 5). 
Sialyltransferase kinetic parameters for the TEV/EndoF1 cleaved product and the GFP fusion were 
similar (Supplementary Table 4), indicating the GFP fusion did not alter enzyme activity. The catalytic 
domain was concentrated and crystallized, leading to diffraction to 3.1 Å, and the structure was solved by 
SAD phasing, revealing six molecules in the asymmetric unit (Supplementary Table 5). Additional 
diffraction data were obtained to 2.35 Å for a labeled co-complex of ST6GALNAC2 with the donor 
analog, CMP, and the structure was solved by molecular replacement (Fig. 6 and Supplementary Table 
5). This revealed a single Rossmann-like (GT-A variant 2) fold similar to other known GT29 
sialyltransferases9,17,24,25, especially within the conserved “sialylmotif” sequence elements 
(Supplementary Fig. 6). The bound CMP was clearly evident in the electron density at a position 
equivalent to CMP bound in other sialyltransferases (Fig. 6), indicating the sialylmotif scaffold 
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underlying the CMP-NeuAc binding site is conserved17. Significant structural differences were found 
outside the sialylmotif elements, as compared to other sialyltransferases, reflecting the minimal primary 
sequence similarity among the sialyltransferases in the loop regions and secondary structure elements 
involved in acceptor substrate recognition (Supplementary Fig. 6). While structures have been reported 
for three of the four vertebrate GT29 sialyltransferase subfamilies that generate NeuAc-a2,6Gal17,24, 
NeuAc-a2,3Gal9, and NeuAc-a2,8NeuAc25 linkages, the present ST6GALNAC2 structure is the first 
reported for a NeuAc-a2,6GalNAc subfamily member17. Efforts to identify enzyme-CMP-acceptor 
structural co-complexes and perform kinetic analyses of site directed mutants are presently underway and 
will be reported elsewhere.  
DISCUSSION 
The diversity of vertebrate cell surface and secreted glycans are produced by complex biosynthetic 
pathways1,2,4. The overall purpose of the present study was to produce an expression vector library 
enabling production of the 339 enzymes involved in human glycan synthesis, modification, and 
catabolism for enzymatic, structural and functional studies. We initially examined the potential for 
recombinant glycoenzyme expression in E. coli, but found that all the recombinant products were 
insoluble aggregates. As a result, we focused on eukaryotic expression in HEK293 and insect cells. These 
two expression hosts were chosen because they are both amenable to high-throughput profiling of protein 
expression and production can be scaled up in larger volume cultures12,13.  
A variety of fusion tag strategies were tested. Inclusion of the “superfolder” GFP domain led to 
improved protein production and secretion for many of the GTs tested in both human and insect cell 
systems (Fig. 2 and Supplementary Figs. 4B and 4C), as compared to shorter fusion tags. The GFP 
fusion also enabled direct detection and quantitation of recombinant products during expression and 
purification. Thus, all of the glycoenzymes were initially profiled as GFP fusions in HEK293 cells.  
Most of the glycoenzyme fusion constructs were highly expressed in HEK293 cells and a major 
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subset (~65%) was well secreted and could be purified at multi-milligram levels from the culture media. 
The efficiency of secretion was surprisingly variable and did not correlate with overall expression level, 
transmembrane topology or enzyme sequence family. This variability was highlighted for the GT29 
sialyltransferases (Fig. 4 and Supplementary Fig. 4), but was also observed with other GT families 
(Supplementary Table 2). These data suggest each protein coding region has a unique set of folding 
constraints within the eukaryotic secretory pathway that cannot be generalized more broadly even within 
an enzyme structural family. 
Parallel expression studies were also performed in BEVs and a common trend in overall expression 
and secretion levels was observed in both insect and mammalian recombinant hosts. When enzymes with 
equivalent tags were compared, half of the enzymes were secreted at similar levels by the two hosts, 
while the remainder were more highly secreted by either mammalian or insect cells. These data suggest 
host-specific factors can also contribute to secretion efficiency for some recombinant products.  
Additional factors can also contribute to the efficiency of protein production in eukaryotic cells. In 
vivo, many of the full length GTs are transmembrane proteins that can assemble into homo-dimers or 
hetero-oligomeric complexes with other proteins26 and sequences proximal to the TMD can also play 
roles in oligomer formation27. Thus, removal of the proteins from their transmembrane contexts and the 
lack of co-expression with binding partners may contribute to difficulties in folding or secretion. Initial 
efforts to co-express potential oligomeric partners or to enforce homo-dimerization using the Ig Fc 
domain in the pGEn3 vector did not lead to enhanced protein secretion, but is still being pursued.  
Overall, many of the glycoenzymes designed for secretion could be readily purified from the culture 
media at high yields using IMAC (Fig. 5). In addition, kinetic analysis was performed on several of these 
purified recombinant products before and after tag removal with TEV protease. The results, exemplified 
by ST6GALNAC2 (Supplementary Table 4), indicated that the enzymes had comparable activity as 
GFP fusion proteins or released catalytic domains17,28. As the construct library was being completed, we 
further characterized several of these expression products and the results effectively identified GT 
 14 
substrate specificities28-30, corrected the glycan linkage elaborated by a GT31, resulted in chemoenzymatic 
synthesis of novel glycan structures32, and supported selective exoenzymatic labeling (SEEL)33 of cell 
surface glycans, demonstrating the utility of our expression vector library as a tool for various 
glycoenzyme studies and applications in glycobiology. 
As a proof of concept for the utility of the HEK293 cell expression platform for protein structural 
studies, we focused on ST6GALNAC2, an enzyme that adds a2,6 linked NeuAc residues to the GalNAc 
residue on Core 1 O-glycans34. The enzyme was produced and purified as a GFP fusion protein, tags were 
removed with TEV protease, N-glycans were enzymatically trimmed, and the product was further 
purified, crystallized, and used for structure determination. This effort was enhanced by expressing the 
enzyme in HEK293S (GnTI-) cells23, which allowed glycan cleavage with EndoF117, and metabolic 
incorporation of selenomethionine, which facilitated phasing of diffraction data by single wavelength 
anomalous diffraction17. Thus, a unified workflow was achieved for production and purification of 
glycoenzymes for both enzymatic and structural studies. We have performed structural studies on 
additional glycosylation enzymes as the expression vector library was being completed. These efforts 
have elucidated six additional mammalian GT structures (many in complex with donor and acceptor 
analogs, manuscripts in preparation), as well as the structure of the extracellular domain of a calcium-
sensing receptor with a novel bound ligand35, and two plant xyloglucan modifying enzymes (manuscripts 
in preparation). Thus, it is clear that the constructs, expression systems, and workflows described here for 
glycoenzyme production and purification will provide novel insights into substrate recognition and 
catalysis for this diverse and important set of glycoenzymes and will provide transformative reagents that 
will continue to expand our knowledge in glycochemistry and glycobiology. 
 
METHODS 
Methods, including statements of data availability and any associated accession codes and references, are 
available in the online version of the paper. 
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AviTag, peptide recognition sequence for in vitro biotinylation by the BirA biotin protein ligase; GFP, 
green fluorescent protein; BEV, baculovirus expression vector; IMAC, immobilized metal affinity 
chromatography; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element; BGH, bovine 
growth hormone.  
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FIGURE LEGENDS 
Figure 1. Flow chart for generation of glycoenzyme expression constructs. The general workflow for 
the generation of human glycoenzyme expression constructs is depicted in the flow chart. A master 
glycogene list was developed as described in Experimental Procedures. Construct designs were generated 
based on the presence and location of TMD sequences and cleavable signal sequences and available 
knowledge regarding the location of the enzyme active sites, as described in Experimental Procedures. 
Truncated or full-length coding regions were incorporated into Gateway “donor” vectors by PCR from 
either Mammalian Gene Collection clone templates or human cDNA sources or, in some cases, by gene 
synthesis. Each of the enzyme coding regions contained a TEV protease recognition site appended to 
either the NH2- or COOH-terminal end of the open reading frame depending on the respective fusion 
protein strategy (Supplementary Fig. 1). Thus, a library of all human glycoenzyme constructs 
(“glycogenes”) was captured in donor vectors that could be transferred to Gateway DEST vectors by 
Gateway LR recombination (see Experimental Procedures). Custom mammalian or baculovirus DEST 
vectors were generated harboring additional in-frame fusion tags (Supplementary Figs. 2 and 3) and 
employed to produce glycogene expression constructs for each recombinant host system. Expression and 
secretion of recombinant enzymes were examined by batch-mode transient transfection (HEK293 cells) or 
baculovirus infection (insect cells) followed by separation into cell and media fractions. Secreted products 
were used for protein purification to produce enzyme preparations with utility for enzymology, structural 
studies, enzymatic glycan synthesis and numerous other applications. 
  
Figure 2. Expression and secretion of representative GTs in different NH2-terminal fusion vectors. 
A collection of fourteen GT29 sialyltransferase coding regions were transferred into the pGEn1, pGEn2, 
and pGEn3 NH2-terminal fusion vectors and tested for expression and secretion by transient transfection 
of HEK293 cells. Clarified conditioned media and cell extracts were collected and resolved by SDS-
PAGE with subsequent protein staining. Additional samples of the conditioned media and extracts of cells 
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transfected with the pGEn2 and pGEn3 expression constructs were tested for GFP fluorescence to 
quantify the recombinant products (bar charts for pGEn2 and pGEn3 constructs). Anticipated sizes for the 
sialyltransferase fusion proteins on the SDS-PAGE gels were 37-50 kDa (pGEn1), 64-75 kDa (pGEn2), 
and 91-102 kDa (pGEn3) depending on the coding region and contribution of glycosylation to molecular 
mass.  
 
Figure 3. Expression and secretion of the glycoenzyme constructs in mammalian cells. The full 
collection of all 339 human glycoenzymes as NH2- or COOH-terminal fusion proteins was expressed in 
HEK293 cells and fusion protein production and secretion were profiled (Panel A). Protein coding 
regions were clustered by transmembrane topology and truncation strategy, including enzymes harboring 
NH2-terminal TMDs, which were truncated to delete the transmembrane sequences and replaced with an 
NH2-terminal fusion tag (Type II TMD (truncated)), those harboring an NH2-terminal signal sequence (N-
terminal signal sequence), which were designed for protein fusions as described in Experimental 
Procedures, proteins containing COOH-terminal TMDs (Type I TMD (truncated)), which were truncated 
to delete the TMD and replaced with a COOH-terminal fusion tag, and cytosolic and multipass TMD 
enzymes, which were expressed as full length coding regions containing COOH-terminal fusions. Total 
GFP fluorescence (cells + media) and cell-free media fluorescence values were determined to assess the 
efficiency of fusion protein secretion (% secretion). Fluorescence values were converted into milligram 
quantities of fusion protein per liter as described in Experimental Procedures. The order of the genes in 
each clustered transmembrane topology category was based on the rank order of overall (cell + media) 
expression (yellow circles). The corresponding quantity of secreted fusion protein for each coding region 
is indicated as blue squares. For each protein coding region, the efficiency of fusion protein secretion (% 
secretion) was indicated in the upper panel (grey circles). To examine the relative expression and 
secretion levels within individual GT sequence families (Panel B) the values of secreted (blue bars) and 
cell-associated (pink bars) fusion proteins for individual GT27, GT29, and GT31 glycosyltransferase 
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family members are displayed as stacked bar graphs with the respective gene name listed below each bar. 
The upper panel shows the efficiency of fusion protein secretion (% secretion) for each coding region 
(grey circles).  
 
Figure 4. Comparison of secreted enzyme expression in transfected mammalian cells versus 
baculovirus infected insect cells. The collection of human glycoenzymes was expressed using 
mammalian expression vectors or BEVs in each respective host (Panel A) and protein secretion levels 
were compared. For mammalian cell expression, the pGEn2 or pGEc2 GFP fusion vectors were employed 
and secreted recombinant products were quantified by GFP fluorescence. For BEV expression, the shorter 
His/StrepII tagged constructs were employed and the respective secreted fusion proteins were quantified 
using anti-His tag immunoblots (see Experimental Procedures). The semi-quantitative immunoblot 
intensities (Supplementary Table 2) were converted into arbitrary relative intensity values and compared 
with the values for enzyme secretion in mammalian cells in a 2-dimensional dot plot. The mean and 
standard error for the GFP fluorescence values are indicated by the solid red box and error bars. A trend 
line is shown for the mean values for GFP fluorescence (red dotted line). While the general trend for 
fusion protein secretion in each host system shows a positive correlation, there was significant scatter of 
the expression values in each recombinant host. Since the fusion protein strategy was different in the 
mammalian and BEV constructs, a subset of the constructs comprising the twenty GT29 sialyltransferases 
was generated in the baculovirus large N-terminal tag vector for direct comparison with the equivalent 
pGEn2 mammalian GFP fusion constructs (Panel B). Comparison of secreted GFP fluorescence in the 
baculovirus and mammalian expression vectors indicated a close correlation for a subset of ten 
sialyltransferases (blue diamonds, R2=0.99), while eight were more highly secreted in mammalian cells 
(red squares) and two were more highly secreted in BEVS (green triangles). 
 
Figure 5. Purification of secreted recombinant fusion proteins. The collection of recombinant 
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constructs encoding the twenty GT29 sialyltransferases were expressed in HEK293 cells (Panel A) and 
BEVs (Panel B) and the conditioned media were used for protein purification by IMAC. Samples 
corresponding to the crude expression media (M), the column run-through fractions (R), and imidazole 
elution fractions (E) from each enzyme purification were analyzed, and the data are shown with genes 
clustered by enzyme specificity subfamily17. GFP fluorescence values were also obtained for each fraction 
and are plotted at the top of each panel for the media (blue bars), column run-through (red bars), and 
elution (green bars) fractions. Most of the glycosylated sialyltransferase GFP fusion proteins were visible 
by protein staining as ~55-75 kDa polypeptides with the exception of ST6GALNAC1, which was 
expressed as a ~110 kDa glycosylated fusion protein. 
 
Figure 6. Structure of human ST6GALNAC2. The structure of human ST6GALNAC2 was solved by 
X-ray diffraction using a recombinant enzyme preparation generated by transient transfection of 
HEK293S (GnTI-) cells as described in Experimental Procedures. The structure represents a single 
Rossmann-like (GT-A variant 2) fold17 with 6 b-strands in the domain core and 17 a-helical segments and 
loop regions (a-helices and b-sheets are labeled in Panel D numbered from the NH2-terminus). There are 
six protomers in the crystallographic asymmetric unit and some of the units contain disordered loops of 
varying lengths. The images in Panels A-E represent Chain D, which contains a single 3 residue 
disordered loop between helix a4 and strand b1 (magenta line in Panels C and D). Panels A and B 
represent a view from the top of the active site, where the bound donor analog, CMP, is shown in yellow 
stick representation. Panels C and D show a cartoon representation of the protein structure at 90° 
rotations relative to Panel A, while Panel B shows a surface representation in the same orientation as 
Panel A. The position of the His351 residue, the predicted catalytic base in the structure by comparison to 
structures of other GT29 sialyltransferases17, is shown in cyan stick representation. Weak electron 
densities for monosaccharide residues were found extended from the amide side chains of Asn85, 
Asn130, and Asn161 as predicted for each residue being found within an NxS glycosylation sequon 
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(where x is any amino acid except Pro). The position of the respective Asn side chain is indicated by a 
white stick representation and a magenta sphere for the amide nitrogen where the N-glycan is attached. 
Four Cys residues are found in the structure, with each participating in a disulfide bond. The NH2 terminal 
residue in the structure, Cys66, is disulfide bonded to Cys148, while a disulfide bond links Cys151 with 
Cys317 (white stick representations with yellow sulfur residues shown as spheres). The full length 
ST6GALNAC2 is a transmembrane, Golgi-localized enzyme in vivo and contains a non-conserved 37 
amino acid linker “stem region” between the transmembrane span and the catalytic domain represented as 
a green line in Panel D. Extensive interactions were identified between the bound CMP donor analog and 
the binding site (Panel E), including polar interactions (green dotted lines) and a hydrophobic stacking 
with Phe325.  
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Online Methods 
Choice of protein coding regions for recombinant expression: A comprehensive list of human 
glycoenzymes was identified in prior efforts to profile glycogene transcription in mouse cells4. Starting 
with this comprehensive list of >700 glycogenes, we targeted 339 coding regions to generate expression 
constructs comprising all known human GTs involved in glycan extension, GHs involved in glycan 
catabolism and processing, STs involved in glycan modification, as well as a collection of additional 
genes involved in glycan elaboration, modification, or catabolism (Supplementary Table 2). 
Truncation and fusion protein strategies for glycoenzyme expression: Each glycoenzyme coding 
region on the target list was examined for sequence features in the UniProt database14 to determine the 
presence of TMDs, NH2-terminal signal sequences, COOH-terminal KDEL ER retention sequences36, or 
known catalytic residues. In general, proteins containing NH2-terminal TMDs (type II transmembrane 
proteins) were designed to truncate all sequences spanning from the initiating Met residue to the first 
charged residues at the luminal boundary of the TMD. These proteins were all designed as NH2-terminal 
fusions to a TEV protease recognition peptide sequence16 during transfer to Gateway donor vectors 
(Supplementary Fig. 1). Proteins containing COOH-terminal TMDs were designed to truncate the TMD 
between the first charged residue on the luminal side of the TMD and the COOH-terminus of the protein 
(Supplementary Fig. 1). A TEV protease recognition sequence was appended to the COOH-terminus of 
the coding region during transfer to the Gateway donor vector (Supplementary Fig. 1). Proteins 
containing NH2-terminal signal sequences were generally designed as full length coding regions with a 
COOH-terminal TEV site extension added in place of the termination codon during transfer to the 
Gateway donor vectors. Many of these latter enzymes were also designed to truncate the NH2-terminal 
signal sequence and subsequent NH2-terminal fusion to the TEV site sequence. Proteins containing 
multipass TMDs, internal TMDs, or soluble cytosolic proteins were generally designed as full length 
coding regions and had a COOH-terminal TEV extension added in place of the termination codon during 
transfer to the Gateway donor vectors. In some of these latter cases NH2-terminal TEV fusions were also 
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generated to test alternative tagging strategies for protein expression.  
Isolation of protein coding regions and capture as Gateway donor clones: Three strategies were 
employed to isolate full length or truncated protein coding regions with appropriate TEV protease 
cleavage site fusions and flanking attL recombination sites in Gateway donor vectors. First, full length 
human cDNA clones were identified within the Mammalian Gene Collection (MGC)18 and plasmid DNAs 
encoding each respective coding region were used as templates for gene-specific PCR amplification. 
Gene-specific primer sequences were synthesized (Eurofins MWG Operon, Louisville, KY) as shown in 
Supplementary Figure 1, with 5’ extensions to initiate the synthesis of the attB recombination and TEV 
protease recognition sites based on the design for truncation and fusion. PCR amplification products were 
generated using 0.1 µM gene specific primers, 100 ng plasmid DNA, and AccuPrime Pfx DNA 
Polymerase (ThermoFisher Scientific) in a total volume of 50 µl. PCR conditions were denaturation at 
94°C for 2 min followed by 15 PCR cycles comprised of 94°C denaturation for 15 seconds, annealing at 
57°C for 1 minute and extension at 68°C for 2 min. After the first round of amplification, 20 µl of the 
gene specific PCR reaction was then subjected to a second round of amplification using a pair of 
universal primers and identical PCR reaction conditions described above to complete the synthesis of the 
attB sites as indicated in Supplementary Figure 1. PCR products were then used directly for Gateway 
recombination with the pDONR221 vector in BP Clonase II reactions with a final volume of 10 µl, as 
described by the manufacturer (ThermoFisher Scientific). The reaction products were transformed into 
the 5-alpha competent E. coli strain (New England Biolabs, Ipswich, MA), and plated on LB plates 
containing kanamycin. The resulting plasmid clones were screened by restriction mapping and verified by 
DNA sequencing of the entire coding region.  
For genes that were not available in MGC or not successfully amplified from MGC clone templates, 
an alternative amplification approach was employed. A library of human RNAs (FirstChoice Human 
RNA Survey Panel, ThermoFisher Scientific) was reverse transcribed using 500 ng RNA, a mixture of 
random hexamers and oligo (dT)20 primers and a reaction mix supplied with the SuperScript II First 
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Strand Synthesis System, as described by the manufacturer (ThermoFisher Scientific). Test amplifications 
were performed using respective gene-specific primers, the human cDNAs, and Phusion DNA 
polymerase reaction mix (ThermoFisher Scientific) as described above. Annealing temperatures, 
extension times, primer concentrations, and cycle numbers were varied to identify optimal conditions for 
PCR amplification of the predicted coding region. Once optimal primary amplification conditions were 
identified, the resulting PCR products were purified using a QiaQuick PCR purification kit (Qiagen) and 
subjected to a second round amplification as described above using the universal primers shown in 
Supplementary Figure 1. Second round amplification products were isolated using the QiaQuick PCR 
purification kit, subjected to Gateway BP Clonase recombination into the pDONR221 vector, and 
transformed into 5-alpha competent E. coli as described above. The resulting plasmid clones were 
verified by DNA sequencing of the entire coding region. 
In instances where amplification of coding regions from MGC or cDNA sources was unsuccessful, or 
when coding regions were poorly expressed, the coding regions were generated by gene synthesis. 
Coding region designs containing TEV fusion sequences and flanking attL1 and attL2 recombination 
sites (Supplementary Tables 2 and 3) were synthesized with human codon optimization (GeneArt gene 
synthesis, ThermoFisher Scientific) and subcloned into a vector backbone containing a kanamycin 
resistance marker (pMK-RQ). The gene synthesis products in this vector backbone were equivalent to the 
pDONR221 constructs and were used directly for recombination into Gateway DEST expression vectors. 
Generation of mammalian expression vector backbones as Gateway DEST vectors: Five custom 
Gateway fusion vectors were generated for mammalian cell expression using a pGEn2 vector backbone 
originally employed for the expression of rat ST6GAL117. This latter vector was generated by gene 
synthesis (ThermoFisher Scientific) and contains a CMV promoter, artificial intron, woodchuck hepatitis 
virus posttranscriptional regulatory element (WPRE), and bovine growth hormone (BGH) termination 
and polyadenylation sequence to drive transcription and termination of the fusion protein coding region. 
Each of the mammalian Gateway expression vectors was adapted for Gateway recombination as DEST 
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vectors by inclusion of attR sites flanking a selection cassette comprised of ccdB and CmR genes15 
(Supplementary Fig. 2). The fusion sequences in each of the five vectors were distinct, employing either 
NH2-terminal (pGEn1-DEST, pGEn2-DEST, and pGEn3-DEST vectors) or COOH-terminal (pGEc1-
DEST and pGEc2-DEST vectors) fusion sequences adjacent to the selection cassette. Each vector 
component was generated by gene synthesis (ThermoFisher Scientific) and swapped into the original 
synthetic ST6GAL1-pGEn2 vector as restriction fragments to replace the ST6GAL1 and adjoining fusion 
sequences. The pGEn1-DEST vector contains a Kozak sequence followed by an NH2-terminal signal 
sequence derived from the Trypanosoma cruzi lysosomal a-mannosidase37, an 8xHis tag, and a StrepII 
tag19 adjacent to the attR1 recombination site (Supplementary Fig. 2). The pGEn2-DEST vector employs 
the same signal sequence and 8xHis tag, but has an AviTag sequence20 and a “superfolder” GFP domain21 
adjacent to the attR1 recombination site (Supplementary Fig. 2). The pGEn3-DEST vector has the same 
signal sequence, 8xHis tag, AviTag and GFP tag as pGEn2-DEST, but also includes an Ig Fc domain22 
sequence between the GFP and the attR1 site (Supplementary Fig. 2).  
For the pGEc1-DEST and pGEc2-DEST COOH-terminal fusion vectors the CMV promoter and 
artificial intron led directly to the attR1 site followed by the selection cassette (Supplementary Fig. 2). 
For these vectors, the Kozak sequence and initiating Met residue were provided by the glycoenzyme 
donor clones. The fusion protein sequences for these vectors extend downstream of the attR2 site, where 
the pGEc1-DEST vector contained an 8xHis tag and StrepII tag and the pGEc2-DEST vector contained a 
GFP domain, AviTag sequence, and 8xHis tag (Supplementary Fig. 2). Each of these selection cassettes 
and fusion sequences were generated by gene synthesis (ThermoFisher Scientific) and swapped into the 
original ST6GAL1-pGEn2 vector as restriction fragments to replace the ST6GAL1 and adjoining fusion 
sequences. 
Gateway recombination of donor clones into mammalian DEST vectors: Transfer of the 
glycoenzyme coding regions from the donor vectors into the respective mammalian DEST expression 
vectors was accomplished using an LR Clonase reaction. Equal quantities of donor and DEST expression 
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vectors were used for LR Clonase reactions (ThermoFisher Scientific) according to the manufacturer’s 
instructions. The reaction products were transformed into 5-alpha competent E. coli (New England 
Biolabs, Ipswitch, MA), plated on LB plates containing ampicillin, and the resulting plasmid clones were 
screened by restriction mapping and verified by DNA sequencing of the entire coding region. 
Small-scale transient transfection of mammalian expression vectors into HEK293 cells: FreeStyle 
293-F cells (ThermoFisher Scientific) were maintained in suspension at 0.5–3.0×106 cells/mL in a 
humidified CO2 platform shaker incubator at 37°C using serum free Freestyle 293 expression medium 
(ThermoFisher Scientific). FreeStyle 293F cells were grown to a density of ~2.5×106 cells/ml and 
transfected by direct addition of 4.5 µg/ml of the respective expression plasmid DNA and 10 µg/ml 
polyethylenimine (linear 25 kDa PEI, Polysciences, Inc, Warrington, PA) to the suspension cultures as 
previously described12. The cultures were diluted 1:1 with Freestyle 293 expression medium containing 
4.4 mM valproic acid (2.2 mM final) 24 h after transfection and protein production was continued for 
another 4-5 days at 37°C.  
Construction of baculovirus-based Gateway DEST vectors: Three different baculovirus DEST 
vectors were constructed for Gateway insertion of glycoenzyme coding sequences, as illustrated in 
Supplementary Figure 3. Each comprised a baculovirus genome of ~135-140 Kbp lacking the viral 
chitinase and cathepsin-like protease genes with key genetic features added to their polyhedrin loci. 
Starting with orf603, which has the opposite orientation, the features of the NH2 terminal tag fusions 
extending downstream in the 5’ to 3’ direction include the baculoviral polyhedrin promoter (pH), a Kozak 
consensus sequence, an ATG initiator codon, and sequences encoding either a “short” tag consisting of 
the honeybee prepromellitin signal peptide38, an 8xHis tag, and a StrepII tag, or a “long” tag consisting of 
the same signal sequence and 8xHis tag followed by an AviTag sequence and superfolder GFP domain 
followed by an attR1 site (Short N-term fusion and GFP N-term fusion baculovirus DNAs, respectively, 
in Supplementary Fig. 3). The first attR1 site in both of these “N-term tag fusion” vectors is followed by 
a herpes simplex virus 1 thymidine kinase gene, which is used for negative selection, and the E. coli b-
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galactosidase gene, which is used to identify parental virus clones after Gateway recombination, and these 
markers are followed by the second attR site (Supplementary Fig. 3). In contrast, the baculovirus DEST 
vector designed for COOH terminal tag fusions includes the baculovirus orf603 and polh promoter 
followed directly by the thymidine kinase and b-galactosidase genes, which are flanked by attR sites 
(Supplementary Fig. 3). In addition, in this DEST vector, the downstream attR site is followed by 
sequences encoding a short tag consisting of StrepII and 8xHis tags. Each of the baculovirus-based 
Gateway DEST vectors includes transcriptional termination signals located within the 3’UTR of the 
baculovirus polyhedrin gene, just upstream of orf1629 (Supplementary Fig. 3). 
Gateway recombination of donor clones into baculovirus DEST vectors and isolation of 
recombinant baculovirus expression vectors: The donor clones described above were used to insert 
sequences encoding glycoenzymes and TEV cleavage sites into the baculovirus DEST vectors, also 
described above, by Gateway recombination. The encoded TEV cleavage sites were designed to appear 
on the COOH- or NH2-terminal sides of the tags encoded by the NH2 terminal or COOH terminal tag 
fusion vectors, respectively. Gateway recombination was performed in LR Clonase (ThermoFisher 
Scientific) reactions performed with a mixture of each donor plasmid and baculovirus DEST vector, 
according to the manufacturer’s instructions. Following the addition of Cellfectin (ThermoFisher 
Scientific) and a short incubation period, each LR reaction was used to transfect Sf9 cells seeded at a 
density of 0.8×106 cells/well into 6-well plates. The cells were incubated for 5 h at 28°C, then the 
transfection mixture was removed and replaced by insect cell growth medium containing 100 µM 
gancyclovir. The cells were incubated for another 5 days at 28°C for baculovirus progeny production with 
gancyclovir selection against the parental virus. Cell free media containing these progeny were then 
harvested and used to isolate individual baculovirus clones by plaque assays in the presence of X-gal, as 
previously described13. After 7-10 days, at least three plaque purified (PP1) clones with white plaque 
phenotypes were picked, amplified in Sf9 cells, and the resulting PP1P1 virus stocks were assayed for 
glycoenzyme expression and secretion by immunoblotting with an anti-His tag antiserum, as previously 
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described13. Once identified, samples of the PP1P1 baculovirus clones passing this screen were amplified 
to PP1P2 by infecting fresh Sf9 cell cultures and the PP1P2 stocks were titered by plaque assay and 
finally used to document glycoenzyme production and secretion levels, as described below. 
Recombinant glycoenzyme production in insect cells: Glycoenzyme production and secretion in the 
baculovirus-insect cell system was comprehensively documented by performing small scale infections in 
Sf9 cells, as previously described13. Briefly, the cells were seeded at a density of 1×106 cells/well into 6-
well plates in a serum-free growth medium (ESF921; Expression Systems), then infected with individual 
baculovirus vectors at a multiplicity of infection of 5 plaque forming units/cell. At 48 h post-infection, the 
cells were scraped into the media, the cell-free media were harvested, and the cell pellets were boiled in 
SDS-PAGE sample buffer. Samples of the total cell lysates and cell free supernatants, which were also 
mixed with SDS-PAGE sample buffer and boiled, were then analyzed by SDS-PAGE with Coomassie 
blue staining or immunoblotting using PVDF membranes (Immobilon-P, Millipore, Billerica, MA) and an 
anti-His tag antibody (ThermoFisher Scientific), as previously described13, to produce the results shown 
in Supplementary Figures 4B-C. 
We also performed mid-scale production runs in the baculovirus-insect cell system using a subset of 
BEVs encoding 20 different members of the GT29 sialyltransferase family. Briefly, Sf9 cells were seeded 
into 50 mL shake flasks in ESF921 and allowed to reach a density of ~1×106 cells/mL in a shaking 
incubator set at 125 rpm and 28°C. The cells were then gently centrifuged and each culture was infected 
with a BEV encoding a tagged sialyltransferase catalytic domain at a multiplicity of infection of five 
plaque-forming units/cell, as previously described13. At 48 h post-infection, the cell-free supernatant was 
harvested, ultracentrifuged to remove extracellular baculovirus and debris, and the resulting supernatant 
was used to affinity purify the secreted sialyltransferase products, as previously described13, except we 
used ProBond nickel chelating resin (ThermoFisher Scientific). Finally, we analyzed samples of the cell 
free supernatants (starting material), unbound fraction (supernatants obtained after ProBond absorption), 
and elution fractions by SDS-PAGE with Coomassie blue staining or immunoblotting, as described 
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above. In separate assays, we monitored GFP fluorescence in the starting material, flow through, and 
elution fractions, as described below. 
Detection of recombinant glycoenzymes from HEK293 cells: For small-scale screening of fusion 
protein expression in transiently transfected HEK293 cells, aliquots of the cell suspensions were 
harvested and subjected to direct GFP fluorescence measurement on a SpectraMAX GeminiXS 
microplate reader (Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 450 nm and 
emission wavelength of 515 nm. The cultures were then clarified by centrifugation at 2500 rpm for 10 
min in a microfuge and the supernatants were subjected to GFP fluorescence measurement as described 
above. Fluorescence values in the supernatants were subtracted from total culture fluorescence values to 
determine cell-associated fluorescence. A purified recombinant form of a GFP fusion protein expressed in 
pGEn2 (ROBO1-pGEn239) was used to derive a factor we used to convert GFP fluorescence values to 
milligrams of recombinant protein. Aliquots of the clarified cell supernatant and cell pellets were also 
boiled in SDS-PAGE sample buffer and analyzed by SDS-PAGE with Coomassie blue staining or 
immunoblotting, as described above, except a mouse anti-poly-His tag antibody (Qiagen, Inc., 
Germantown, MD) was used.  
Scale-up of recombinant glycoenzyme production in HEK293 cells for structural studies: 
Recombinant enzyme production for protein structural studies was performed in a mutant HEK293 cell 
line defective in Asn-linked glycan maturation (HEK293S (GnTI-) cells23 (ATCC) using modifications of 
workflows based on prior structural studies on rat ST6GAL117. The HEK293S (GnTI-) cells were 
maintained at 0.5-3.0×106 cells/ml in a humidified CO2 platform shaker incubator at 37°C in cell culture 
medium comprised of 9 volumes Freestyle 293 expression medium (ThermoFisher Scientific) and 1 
volume Ex-cell 293 serum-free medium (Sigma) (9:1 medium). Transfections were accomplished by 
resuspending cells at ~2.8×106 cells/ml in fresh 9:1 medium, followed by direct addition of 4.5 µg/ml of 
the plasmid DNA (ST6GALNAC2-pGEn2) and 10 µg/ml polyethyleneimine to the suspension cell 
culture. The cultures were diluted 1:1 with 1:9 medium containing 4.4 mM valproic acid (2.2 mM final) 
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12-24h after transfection, and protein production was continued for a further 4-5 days at 37°C.  
In cases where recombinant proteins were labeled with selenomethionine (Sigma-Aldrich), cells were 
transfected as above, and the media were exchanged 12 h after transfection for custom methionine-free 
Freestyle 293 expression medium (ThermoFisher Scientific) for 6 h to deplete methionine pools. The 
cultures were subsequently resuspended in methionine-free Freestyle 293 expression medium containing 
60 mg/L selenomethionine at density of 2.0×106 cells/ml. The protein production was continued for 4 –5 
days at 37 °C before harvest of the conditioned medium. 
Protein purification, deglycosylation, and tag removal employed workflows similar to prior structural 
studies on rat ST6GAL117. The conditioned culture medium was harvested, clarified by centrifugation, 
passed through a 0.45 µm filter (Millipore) and adjusted to contain 20 mM imidazole, 20 mM NaCl, and 3 
mM sodium phosphate, pH 7.2, and loaded onto a 25 ml of Ni2+-NTA Superflow (Qiagen, Valencia, CA) 
column equilibrated with 20 mM HEPES, 300 mM NaCl, 20 mM imidazole, pH 7.2. The column was 
washed with column buffer and eluted successively with column buffer containing 50 mM imidazole, 100 
mM imidazole, and finally 300 mM imidazole. The 300 mM imidazole elution fractions were pooled and 
concentrated to 1 mg/ml using a 10 kDa molecular mass cutoff ultrafiltration membrane (Millipore, 
Billerica, MA). Purified recombinant TEV protease and EndoF1 expressed and purified as described17 
were added at ratios of 1:15 and 1:8 relative to the GFP-ST6GALNAC2, respectively, and incubated at 
room temperature for 3-5 hours, followed by 4°C overnight to cleave the tag and glycans. The protein 
mixture was diluted 15-fold in 50 mM sodium phosphate, pH 7.2, 800 mM NaCl, 10% glycerol to lower 
the imidazole concentration and loaded onto a 25 ml Ni2+-NTA column to remove the fusion tag and His-
tagged TEV protease and EndoF1. The protein preparation was then concentrated by ultrafiltration and 
further purified on a Superdex 75 column (GE Healthcare) preconditioned with a buffer containing 20 
mM HEPES, 200 mM NaCl, 60 mM imidazole, pH 7.2. Peak ST6GALNAC2 fractions were collected 
and concentrated by ultrafiltration to 9-10 mg/ml for crystallization.  
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Kinetic Analysis: Sialyltransferase enzyme activity was measured using a phosphatase-coupled assay 
(malachite green phosphate detection kit, R&D Systems, Minneapolis, MN) essentially as previously 
described17, except asialofetuin was used as the acceptor. Assays were performed in 50 µl containing 100 
mM MES, pH 6.5, 0.1 µg of recombinant ST6GALNAC2, CD73 (0.5 ng/ l), asialofetuin (250 µM for 
routine assays or varied from 25 to 800 µM for kinetic analysis), and CMP-Neu5Ac (250 µM for routine 
assays or varied from 25 to 1000 µM for kinetic analysis). Following a 30 min incubation at 37 °C, the 
reaction was stopped by addition of the malachite green phosphate detection reagents and further 
incubation as described by the manufacturer17. Absorbance at 620 nm was determined and compared with 
equivalent analyses for a phosphate standard curve. Enzyme activity values (nanomoles/min) were 
determined at varied substrate concentrations, and kinetic data were fit using GraphPad Prism software 
(version 5.00, La Jolla, CA) to determine Km and kcat values.  
Crystallization and structure determination: Crystallization conditions for selenomethionine-labeled 
human ST6GALNAC2 were initially screened using the high throughput crystallization facility at the 
Hauptman Woodward Medical Research Institute40. Based on the results, the protein was crystallized 
using the microbatch method at 4°C with a protein solution (2 µl) containing the enzyme (9.3 mg/ml) in a 
buffer consisting of 20 mM HEPES (pH 7.4), 200 mM NaCl, 60 mM imidazole, and recombinant peptide 
N-glycosidase (1:900) expressed in E. coli41. The protein solution was mixed with 2 µl of the precipitant 
solution comprising 100 mM ammonium sulfate, 100 mM sodium citrate (pH 4.2), and 24% (w/v) PEG 
20K. The crystals appeared after several days, were harvested after one week, cryoprotected by 
supplementing the crystallization solution with 20% (v/v) glycerol, and flash-frozen in liquid nitrogen for 
data collection at 100°K. A single-wavelength anomalous diffraction data set to resolution 2.9 Å was 
collected at the peak absorption wavelength (0.9792 Å) of selenium at the 24-ID-E beam line of the 
Advanced Photon Synchrotron (APS). The diffraction images were processed with the HKL2000 
package42. The crystals of the apo enzyme belong to space group P1 and there are six protomers in the 
asymmetric unit (ASU) of the crystal. The selenium sites were determined by the direct method using 
 32 
SHELX43, which located 23 of 30 possible selenium sites. A crude model was subsequently built using 
SOLVE/RESOLVE44. The majority of the initial model comprising six protomers were manually built 
with the program XtalView45.   
The selenomethionine-labeled ST6GALNAC2 in complex with CMP was subsequently crystallized 
using the crystallization condition for the apo enzyme, except the protein solution contained 5 mM CMP. 
A single-wavelength native diffraction data set to resolution 2.35 Å was collected at the 14-1 beam line of 
the SLAC National Accelator Laboratory (SLAC). The diffraction images were processed with the 
HKL2000 package46. The crystals of the CMP-complex also belong to space group P1, albeit having 
different cell parameters as compared with those of the apo enzyme crystal, and there are six protomers 
per ASU of the crystal. The structure was determined using the molecular replacement method with the 
program COMO47. All stages of the structure refinement were performed using the crystallographic 
programs CNS 1.348 and PHENIX49. PHENIX was also used in the last stage of refinement. The statistics 
for data collection and refinement are shown in Supplementary Table 5. 
Availability of constructs:  
All mammalian glycoenzyme donor constructs and final mammalian expression constructs are 
archived in the DNASU plasmid repository (dnasu.org). Baculovirus stocks are available directly from 
the Jarvis laboratory (dljarvis@uwyo.edu). A website has been generated (glycoenzymes.ccrc.uga.edu) 
summarizing the strategy for construct designs, and provides annotations and sequences of all 
glycoenzyme constructs in the library, as well as links to construct availability at DNASU. 
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